HIV-AIDS - Urologic Considerations

Urologic Clinics of North America

Volumn 35, Issue 1, 2008, Pages 59-68

  Lebovitch, Steve ^a   Mydlo, Jack H ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTIRETROVIRUS AGENT; BLEOMYCIN; CIPROFLOXACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FLUOROURACIL; INDINAVIR; INTERFERON; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; PACLITAXEL; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SILDENAFIL; VINCA ALKALOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CARCINOMA IN SITU; COMORBIDITY; CRYOTHERAPY; DISEASE ASSOCIATION; ENTEROBACTER; EPIDIDYMITIS; ERECTILE DYSFUNCTION; ESCHERICHIA COLI; FERTILITY; FUNGAL STRAIN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KAPOSI SARCOMA; KIDNEY FAILURE; LYMPHOMA; MALE FERTILITY; MICTURITION DISORDER; NECROTIZING COLITIS; NONHODGKIN LYMPHOMA; ORCHITIS; PENIS CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; PUUMALA VIRUS; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; UNITED STATES; URINARY TRACT INFECTION; URINE CULTURE; UROLITHIASIS; VIRUS LOAD; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-ASSOCIATED NEPHROPATHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; UROLOGIC DISEASES;

EID: 36448935658     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.09.001     Document Type: Review

References (80)

1. UNAIDS/WHO. AIDS epidemic update: December 2006. http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf. Accessed May 20, 2007.
2. Hoepelman A.I., van Buren M., van den Broek J., et al. Bacteriuria in men infected with HIV-1 is related to their immune status (CD4+ cell count). AIDS 6 (1992) 179-184
3. Lee L.K., Dinneen M.D., and Ahmad S. The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome. BJU Int 88 (2001) 500-510
4. Hyun G., and Lowe F.C. AIDS and the urologist. Urol Clin North Am 30 (2003) 101-109
5. Miles B.J., Melser M., Farah R., et al. The urological manifestations of the acquired immunodeficiency syndrome. J Urol 142 (1989) 771-773
6. Heyns C.F., and Fisher M. The urological management of the patient with acquired immunodeficiency syndrome. BJU Int 95 (2005) 709-716
7. Kwan D.J., and Lowe F.C. Acquired immunodeficiency syndrome: a venereal disease. Urol Clin North Am 19 (1992) 13-24
8. Steele B.W., and Carson C.C. Recognizing the urologic manifestations of HIV and AIDS. Contemp Urol 9 (1997) 39-53
9. Kaplan M.S., Wechsler M., and Benson M.C. Urologic manifestations of AIDS. Urology 30 (1987) 441-443
10. O'Regan S., Russo P., Lapointe N., et al. AIDS and the urinary tract. J Acquir Immune Defic Syndr 3 (1990) 244-251
11. Corman J.M., Moody J.A., and Aronson W.J. Fournier's gangrene in a modern surgical setting: improved survival with aggressive management. BJU Int 84 (1999) 85-88
12. Leport C., Rousseau F., Perronne C., et al. Bacterial prostatitis in patients infected with the human immunodeficiency virus. J Urol 141 (1989) 334-336
13. Wise G.J., and Shteynshlyuger A. How to diagnose and treat fungal infections in chronic prostatitis. Curr Urol Rep 7 4 (2006) 320-328
14. Hoffmann C., and Mulcahy F. ART 2006. In: Hoffmann C., Rockstroh J.K., and Kamps S.B. (Eds). HIV medicine 2006 (2006), Flying, Paris, Cagliari, Wuppertal 284-285. http://www.HIVMEDICINE.com Accessed May 20, 2007
15. Meraviglia P., Angeli E., Del Sorbo F., et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 16 (2002) 2089-2093
16. Heylen R., and Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV-positive patients: part 2. Genitourin Med 73 (1997) 5-11
17. Tashima K.T., Horowitz J.D., and Rosen S. Indinavir nephropathy. N Engl J Med 336 (1997) 138-139
18. Bruce R.G., Munch L.C., Hoven A.D., et al. Urolithiasis associated with the protease inhibitor indinavir. Urology 50 (1997) 513-518
19. Daudon M., Estepa L., Viard J.P., et al. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet 349 (1997) 1294-1295
20. Nadler R.B., Rubenstein J.N., Eggener S.E., et al. The etiology of urolithiasis in HIV-infected patients. J Urol 169 (2003) 475-477
21. Schwartz B.F., Schenkman N., Armenakas N.A., et al. Imaging characteristics of indinavir calculi. J Urol 161 (1999) 1085-1087
22. Collin F., Chene G., Retout S., et al. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults. Ther Drug Monit 29 2 (2007) 164-170
23. Kopp J.B., Miller K.D., Mican J.M., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127 (1997) 119-125
24. Crum-Cianflone N.F., Bavaro M., Hale B., et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS 21 1 (2007) 9-19
25. Srinivas-Shankar U., and Wu F.C.W. Drug insight: testosterone preparations. Nat Clin Pract Urol 3 12 (2006) 653-665
26. Karlovsky M., Lebed B., and Mydlo J.H. Increasing incidence and importance of HIV/AIDS and gonorrhea among men aged >50 in the US in the era of erectile dysfunction therapy. Scan J Urol Nephrol 38 (2004) 247-252
27. Benotsch E.G., Seeley S., Mikytuck J.J., et al. Substance use, medications for sexual facilitation, and sexual risk behavior among traveling men who have sex with men. Sex Transm Dis 33 12 (2006) 706-711
28. Lamba H., Goldmeier D., Mackie N.E., et al. Antiretroviral therapy is associated with sexual dysfunction and with increased serum estradiol levels in men. Int J STD AIDS 15 4 (2004) 234-237
29. Lallemand F., Salhi Y., Linard F., et al. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr 30 2 (2002) 187-190
30. Schrooten W., Colebunders R., Youle M., et al., Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 15 8 (2001) 1019-1023
31. Sollima S., Oslo M., Muscia F., et al. Protease inhibitors and erectile dysfunction. AIDS 15 17 (2001) 2331-2333
32. Murray C., Barry M.G., Ryan M., et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 13 15 (1999) F101-F107
33. Crum N.F., Furtek J.K., Olson P.E., et al. A review of hypogonadism and erectile dysfunction and HIV-infected men during the pre-and post HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS 19 10 (2005) 655-671
34. Alciati A., Gallo L., Monforte A., et al. Major depression-related immunological changes and combination antiretroviral therapy in HIVB-seropositive patients. Hum Psychopharmacol 22 1 (2007) 33-40
35. Shiri R., Koskomaki J., Tammela T.L., et al. Bidirectional relationship between depression and erectile dysfunction. J Urol 177 2 (2007) 669-673
36. Fava M., Nurnberg H.G., Seidman S.N., et al. Efficacy and safety of sildenafil in men with serotonergic antidepressant associated erectile dysfunction: results from a randomized, double blind placebo controlled trial. J Clin Psychiatry 67 2 (2006) 240-246
37. Boyarsky B.K., Haque W., Rouleau M.R., et al. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 9 4 (1999) 175-179
38. Ende A.R., Lo Re V., DiNubile M.J., et al. Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDS 20 2 (2006) 75-78
39. Nurnberg H.G., and Duttagupta S. Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. Am J Ther 11 1 (2004) 9-12
40. Sadeghi-Nejad H., Watson R., Irwin R., et al. Lecture 5: erectile dysfunction in the HIV-positive male. A review of medical, legal and ethical considerations in the age of oral pharmacotherapy. Int J Impot Res 12 Suppl 3 (2000) S49-S53
41. Leibovitch I., and Goldwasser B. The spectrum of acquired immunodeficiency syndrome-associated testicular disorders. Urology 44 (1994) 818-824
42. Pudney J., and Anderson D. Orchitis and human immunodeficiency virus type I infected cells in reproductive tissues from men with the acquired immune deficiency syndrome. Am J Pathol 139 (1991) 149-160
43. DePaepe M.E., and Waxman M. Testicular atrophy in AIDS: a study of 57 autopsy cases. Hum Pathol 20 (1989) 210-214
44. Sonnenberg-Schwan U., Gilling-Smith C., and Weigel M. HIV and wish for parenthood. In: Hoffmann C., Rockstroh J.K., and Kamps S.B. (Eds). HIV medicine 2006 (2006), Flying, Paris, Cagliari, Wuppertal 667-678. http://www.HIVMEDICINE.com Accessed May 20, 2007
45. Semprini A.E., Levi-Setti P., Bozzo M., et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 340 (1992) 1317-1319
46. Garrido N., Meseguer M., Bellver J., et al. Report of the results of a 2 year programme of sperm wash and ICSI treatment for human immunodeficiency virus and hepatitis C virus serodiscordant couples. Hum Reprod 19 (2004) 2581-2586
47. Gyrtrup H.J., Kristiansen V.B., Zachariae C.O., et al. Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol 29 (1995) 295-298
48. Menendez V., Espuna M., Perez A., et al. Neurogenic bladder in patients with acquired immunodeficiency syndrome. Neurourol Urodyn 14 (1995) 253-257
49. Hermieu J.F., Delma V., and Boccon-Gibod L. Micturition disturbances and human immunodeficiency virus infection. J Urol 156 (1996) 157-159
50. Rieke A. HIV and renal function. In: Hoffmann C., Rockstroh J.K., and Kamps S.B. (Eds). HIV medicine 2006 (2006), Flying, Paris, Cagliari, Wuppertal 571-584. http://www.HIVMEDICINE.com Accessed May 20, 2007
51. Krieger J.N. Urologic implications of AIDS and HIV infection. In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell-Walsh urology. 9th edition (2006), Elsevier, Philadelphia 386-404
52. Shah S.N., He C.J., and Klotman P. Update on HIV-associated nephropathy. Curr Opin Nephrol Hypertens 15 (2006) 450-455
53. Blattner W.A. Human retroviruses: their role in cancer. Proc Assoc Am Physicians 111 (1999) 563-572
54. Bellan C., De Falco G., Lazzi S., et al. Pathologic aspects of AIDS malignancies. Oncogene 22 (2003) 6639-6645
55. Adjiman S., Zerbib M., Flam T., et al. Genitourinary tumors and HIV1 infection. Eur Urol 18 (1990) 61-63
56. Engels E.A., Pfeiffer R.M., Goedert J.J., et al., for the HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States: 1980-2002. AIDS 20 12 (2006) 1645-1654
57. Patel B, Hanson D, Novak R, et al. Incidence of AIDS defining and non-AIDS defining malignancies among HIV-infected persons [abstract 813]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, February 5-8, 2006.
58. Schoefer H., and Sachs D.L. Kaposi's sarcoma. In: Hoffmann C., Rockstroh J.K., and Kamps S.B. (Eds). HIV medicine 2006 (2006), Flying, Paris, Cagliari, Wuppertal 481-489. http://www.HIVMEDICINE.com Accessed May 20, 2007
59. Tappero J.W., Conant M.A., Wolfe S.F., et al. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 28 (1993) 371-395
60. Pollok R.C.G., Francis N., Cliff S., et al. Kaposi's sarcoma in the kidney. Int J STD AIDS 6 (1995) 289-290
61. Weil D.A., Ruckle H.C., Lui P.D., et al. Kaposi's sarcoma of the testicle. AIDS Read 9 7 (1999) 455-461
62. Lowe F.C., Lattimer D.G., and Metroka C.E. Kaposi's sarcoma of the penis in patients with acquired immunodeficiency syndrome. J Urol 142 (1989) 1475-1477
63. Swierzewski III S.J., Wan J., Boffini A., et al. The management of meatal obstruction due to Kaposi's sarcoma of the glans penis. J Urol 150 (1993) 193-195
64. Klein L.T., and Lowe F.C. Penile gangrene associated with extensive Kaposi's sarcoma in patients with the acquired immunodeficiency syndrome. Urology 46 (1995) 425-428
65. Martin-Carbonero L., Barrios A., Saballs P., et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18 (2004) 1737-1740
66. Tulpule A., Groopman J., Saville M.W., et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95 (2002) 147-154
67. Hoffmann C. Malignant lymphomas. In: Hoffmann C., Rockstroh J.K., and Kamps S.B. (Eds). HIV medicine 2006 (2006), Flying, Paris, Cagliari, Wuppertal 491-503. http://www.HIVMEDICINE.com Accessed May 20, 2007
68. Leibovitch I., Baniel J., Rowland R.G., et al. Malignant testicular neoplasms in immunosuppressed patients. J Urol 155 (1996) 1938-1942
69. Goedert J.J., Purdue M.P., McNeel T.S., et al. Risk of germ cell tumors among men with HIV/acquired immunodeficiency syndrome. Cancer Epidemiol Biomarkers Prev 16 6 (2007) 1266-1269
70. Hausen H.Z., and Villiers E.D. Human papilloma viruses. Annu Rev Microbiol 48 (1994) 427-447
71. Nguyen P., Vin-Christian K., Ming M.E., et al. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 138 6 (2002) 827-828
72. O'Connor J.K., Nedzi L.A., and Zakris E.L. Prostate adenocarcinoma and human immunodeficiency virus: report of three cases and review of the literature. Clin Genitourin Cancer 5 1 (2006) 85-88
73. Manfredi R., Fulgaro C., Sabbatani S., et al. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features: open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev 30 1 (2006) 20-23 [Epub 2006]
74. Quatan N., Nair S., Harrowes F., et al. Should HIV patients be considered a high risk group for the development of prostate cancer?. Ann R Coll Surg Engl 87 6 (2005) 437-438
75. Vianna L.E., Lo Y., and Klein R.S. Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med 7 7 (2006) 471-476
76. Levinson A., Nagler E.A., and Lowe F.C. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 65 1 (2005) 91-94
77. CDC. Preventing occupational HIV transmission to healthcare personnel. February 2002. http://www.cdc.gov/hiv/resources/factsheets/hcwprev.htm. Accessed May 20, 2007.
78. Panlilio A.L., Cardo D.M., Grohskopf L.A., et al. Centers for Disease Control and Prevention: updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR (2005). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm Accessed May 20, 2007
79. Young T., Arens F., Kennedy G., et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 1 (2007) CD002835
80. Schackman B.R., Gebo K.A., Walensky R.P., et al. The lifetime cost of current human immunodeficiency virus care in the United States. [review]. Med Care 44 11 (2006) 990-997